Table 2.

Analysis According to CHA₂DS₂‐VASc‐Determined Risk Groups

	CHA2DS2‐VASc*
	Low		Intermediate		High		P Value
	(n=3467)		(n=2686)		(n=3580)
Sex
Men, %	2507	72.3	2012	74.9	2560	71.5	0.009
Age (y) mean, SD	48.2	11.0	54.4	10.6	58.2	10.5	0.010
≥65 y, %	0	0.0	394	14.7	1134	31.7
Comorbidities
Congestive heart failure, %	0	0.0	610	22.7	2171	60.6	<0.001
Hypertension, %	0	0.0	1330	49.5	3095	86.5	<0.001
Diabetes mellitus, %	0	0.0	240	8.9	1195	33.4	<0.001
Past history of ischemic stroke /TIA, %	0	0.0	0	0.0	604	16.9	<0.001
Vascular disease, %	0	0.0	112	4.2	676	18.9	<0.001
Medication
Antiplatelet drug, %
Cyclooxygenase inhibitor, %	271	7.8	319	11.9	777	21.7	<0.001
ADP receptor antagonist, %	27	0.8	71	2.6	270	7.5	<0.001
Other antiplatelet, %	0	0.0	1	0.0	9	0.3	0.002
Antiulcer drug, %
Proton pomp inhibitor, %	189	5.5	294	10.9	741	20.7	<0.001
H2 blocker, %	172	5.0	212	7.9	371	10.4	<0.001
Other antiulcer drug, %	727	21.0	600	22.3	834	23.3	0.062
Antiarrhythmic drug
Ia, %	307	8.9	184	6.9	223	6.2	<0.001
Ib, %	19	0.5	22	0.8	43	1.2	0.012
Ic, %	535	15.4	421	15.7	410	11.5	<0.001
II, %	387	11.2	308	11.5	601	16.8	<0.001
III, %	5	0.1	10	0.4	111	3.1	<0.001
IV, %	41	1.2	33	1.2	36	1.0	0.665
Digitalis, %	134	3.9	139	5.2	218	6.1	<0.001
HAS‐BLED mean, SD	0.12	0.33	0.39	0.58	0.80	0.82	<0.001

CHA2DS2‐VASc scores are interpreted as follows: low risk was 0 in men and 1 in women; intermediate risk was 1 in men and 2 in women; high risk was ≥2 in men and ≥3 in women.